Alecensa


Dose and administration

DOSING SCHEDULE IN
ALK+ RESECTED AND ADVANCED NSCLC

Infographic.png
600mg.svg
twice-day.svg
with-food.svg

Oral medication; swallowed whole

  • In patients with underlying severe hepatic impairment (Child-Pugh C) the recommended dose is 450 mg orally twice daily with food1
  • If a planned dose of ALECENSA is missed, patients may make up that dose unless the next dose is due within 6 hours1
  • Patients should not take two doses at the same time to make up for a missed dose1
  • If vomiting occurs after taking a dose of ALECENSA, patients should take the next dose at the scheduled time1

DURATION OF TREATMENT 
ALK+ RESECTED NSCLC1

Treat with ALECENSA until 
disease recurrence, unacceptable 
toxicity or for 2 years

DURATION OF TREATMENT ALK+ ADVANCED NSCLC1

Treat with ALECENSA 
until disease progression or 
unacceptable toxicity

exclamation-mark.svg

Please refer to the SmPC for more details on 
monitoring and ALECENSA dose modifications

Explore the ALINA data

Discover

ALECENSA

Explore

*Please refer to the SmPC for more details on dose modifications. †Heart rate <60 bpm.


AE: adverse event; ALK: anaplastic lymphoma kinase; ALT: alanine transaminase; AST: aspartate aminotransferase; bpm: beats per minute; CPK: creatinine phosphokinase; ILD: interstitial lung disease; NSCLC: non-small cell lung cancer; SmPC: Summary of Product Characteristics; ULN: upper limit of normal.


1. Roche. ALECENSA (alectinib) Summary of Product Characteristics. 2024. Available here (accessed July 2024).